Literature DB >> 34028759

Methods for the Study of Renal Fibrosis in Human Pluripotent Stem Cell-Derived Kidney Organoids.

Alejandro Moran-Horowich1, Dario R Lemos2,3.   

Abstract

The mechanisms of kidney injury and fibrosis can now be studied using kidney organoids derived from human pluripotent stem cells (hPSCs). Mature kidney organoids contain nephrons and stromal cells with fibrogenic potential, spatially organized in a manner that resembles the anatomy of the kidney. Organoid nephron damage and interstitial fibrosis can be induced under well-controlled experimental conditions in vitro, making this an ideal system for the study of tissue-intrinsic cell signaling and intercellular crosstalk mechanisms in the absence of systemic signals and immune cells that are present in vivo. Here we describe methods for the generation of kidney organoids from a widely used hPSC line, and for the induction and analysis of nephron damage and interstitial fibrosis.

Entities:  

Keywords:  Fibrosis; Injury; Nephron; Organoid

Year:  2021        PMID: 34028759     DOI: 10.1007/978-1-0716-1382-5_29

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

1.  Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis.

Authors:  Minoru Takasato; Pei X Er; Han S Chiu; Barbara Maier; Gregory J Baillie; Charles Ferguson; Robert G Parton; Ernst J Wolvetang; Matthias S Roost; Susana M Chuva de Sousa Lopes; Melissa H Little
Journal:  Nature       Date:  2015-10-07       Impact factor: 49.962

2.  Interleukin-1β Activates a MYC-Dependent Metabolic Switch in Kidney Stromal Cells Necessary for Progressive Tubulointerstitial Fibrosis.

Authors:  Dario R Lemos; Michael McMurdo; Gamze Karaca; Julia Wilflingseder; Irina A Leaf; Navin Gupta; Tomoya Miyoshi; Koichiro Susa; Bryce G Johnson; Kirolous Soliman; Guanghai Wang; Ryuji Morizane; Joseph V Bonventre; Jeremy S Duffield
Journal:  J Am Soc Nephrol       Date:  2018-05-08       Impact factor: 10.121

3.  Rapid and efficient differentiation of human pluripotent stem cells into intermediate mesoderm that forms tubules expressing kidney proximal tubular markers.

Authors:  Albert Q Lam; Benjamin S Freedman; Ryuji Morizane; Paul H Lerou; M Todd Valerius; Joseph V Bonventre
Journal:  J Am Soc Nephrol       Date:  2013-12-19       Impact factor: 10.121

4.  Generation of nephron progenitor cells and kidney organoids from human pluripotent stem cells.

Authors:  Ryuji Morizane; Joseph V Bonventre
Journal:  Nat Protoc       Date:  2016-12-22       Impact factor: 13.491

5.  Pharmacological GLI2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosis.

Authors:  Rafael Kramann; Susanne V Fleig; Rebekka K Schneider; Steven L Fabian; Derek P DiRocco; Omar Maarouf; Janewit Wongboonsin; Yoichiro Ikeda; Dirk Heckl; Steven L Chang; Helmut G Rennke; Sushrut S Waikar; Benjamin D Humphreys
Journal:  J Clin Invest       Date:  2015-07-20       Impact factor: 14.808

Review 6.  Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis.

Authors:  Gabriela Campanholle; Giovanni Ligresti; Sina A Gharib; Jeremy S Duffield
Journal:  Am J Physiol Cell Physiol       Date:  2013-01-16       Impact factor: 4.249

7.  Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids.

Authors:  Benjamin S Freedman; Craig R Brooks; Albert Q Lam; Hongxia Fu; Ryuji Morizane; Vishesh Agrawal; Abdelaziz F Saad; Michelle K Li; Michael R Hughes; Ryan Vander Werff; Derek T Peters; Junjie Lu; Anna Baccei; Andrew M Siedlecki; M Todd Valerius; Kiran Musunuru; Kelly M McNagny; Theodore I Steinman; Jing Zhou; Paul H Lerou; Joseph V Bonventre
Journal:  Nat Commun       Date:  2015-10-23       Impact factor: 14.919

8.  Nephron organoids derived from human pluripotent stem cells model kidney development and injury.

Authors:  Ryuji Morizane; Albert Q Lam; Benjamin S Freedman; Seiji Kishi; M Todd Valerius; Joseph V Bonventre
Journal:  Nat Biotechnol       Date:  2015-11       Impact factor: 54.908

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.